Skip to main content

Table 2 Details of adverse effects of therapy in both groups.

From: Comparative study of sequential intravesical chemotherapy using gemcitabine and mitomycin C with mitomycin C alone for non-muscle invasive bladder carcinoma- a randomized trial

Parameters

Group A

Group B

P value

 

Gemcitabine + MMC

Mitomycin C(MMC)

 

Dysuria

11.7% (12)

7.2% (7)

NS+

Suprapubic pain

11.7% (12)

9.3% (9)

NS+

Hematuria

3.9% (4)

3.1% (3)

NS+

Chemical Cystitis

7.8% (8)

6.25% (6)

NS+

Local reaction

6.8% (7)

4.16% (4)

NS+

Skin reaction

5.8% (6)

4.16% (4)

NS+

  1. Group A: Gemcitabine & Mitomycin (MMC+Gentamycin)
  2. Group B: Mitomycin C(MMS)
  3. *Statistical significance was analyzed by student t-test
  4. +Statistical significance was analyzed by the chi-square test.